Acurox Drops Niacin, But King And Acura Need New Study For Reformulation
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms will submit NDA for a revised version of their oxycodone formulation Acurox that offers impediments to abuse by snorting or injection but does not contain niacin, which FDA says is ineffective at preventing oral abuse.
You may also be interested in...
Acurox NDA Returns To FDA Without Niacin, But With More Dosing Flexibility
King and Acura are refiling the abuse-resistant oxycodone, this time without the addition of vitamin B3 that FDA and an advisory panel said would do no good at stopping abuse.
Acurox NDA Returns To FDA Without Niacin, But With More Dosing Flexibility
King and Acura are refiling the abuse-resistant oxycodone, this time without the addition of vitamin B3 that FDA and an advisory panel said would do no good at stopping abuse.
King Pharma's Second Quarter Disappoints; Looks to Pain Approvals and Diversification
With the Skelaxin story "over," King is pushing ahead with plans to resubmit abuse-deterrent opioids Remoxy and Acurox for FDA approval and fine-tuning its sales force to improve performance of Embeda.